The CDMO market is poised for growth due to rising R&D spending, increased demand for generics and biologics, patent ...

Alternative methods to the use of animals in pharmaceutical testing are becoming more used and accepted. Laura Lotfi of ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

In this Pharma Matters Q&A, Anshul Gupte of PCI Pharma Services discusses investments and opportunities in sterile ...

MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030 Plan, the health component of 'France 2030', led by the Health Innovation Agency dedicated to ...

For pharmaceutical and life sciences companies ready to embrace this moment, the 10 principles aren't a burden. They're a ...

Lantern has successfully confirmed PTGR1 as a key biomarker that it intends to use to optimize patient selection based on potential tumor sensitivity to the drug candidate LP-184. LP-184 is a ...

In Detroit, they say that we don’t have healthcare in our country, we have sick care. Under the Trump Administration, our ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including ...

Royalty Pharma plc has completed a transaction to monetize remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in cash, resulting in total proceeds of $530 million ...